NGNE Overview

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Wall Street analysts forecast NGNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NGNE is58.00 USD with a low forecast of 46.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Neurogene Inc revenue for the last quarter amounts to 0.00 USD, decreased

Neurogene Inc. EPS for the last quarter amounts to -1.12 USD, increased 12.00

Neurogene Inc (NGNE) has 131 emplpoyees as of March 30 2026.

Today NGNE has the market capitalization of 316.94M USD.